Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
De Meyer
Sandra
S
Hill
Andrew
A
Picchio
Gaston
G
DeMasi
Ralph
R
De Paepe
Els
E
de Béthune
Marie-Pierre
MP
D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D061466:Lopinavir; D009154:Mutation; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D019438:Ritonavir / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; D019438:Ritonavir; D000069454:Darunavir